Carregant...

Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma

Autologous chimeric antigen receptor (CAR) T cells targeted to epidermal growth factor receptor variant III (CAR T-EGFRvIII) have been developed and administered experimentally to treat patients with IDH1 wildtype recurrent glioblastoma (rGBM) (NCT02209376). We report the case of a 59-year-old patie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Durgin, Joseph S., Henderson, Fraser, Nasrallah, MacLean P., Mohan, Suyash, Wang, Sumei, Lacey, Simon F., Melenhorst, Jan Joseph, Desai, Arati S., Lee, John Y. K., Maus, Marcela V., June, Carl H., Brem, Steven, O’Connor, Roddy S., Binder, Zev, O’Rourke, Donald M.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8138201/
https://ncbi.nlm.nih.gov/pubmed/34026647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.669071
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!